Animal disease models are a vital tool to study diseases and associated conditions. Studies on animal models can, in some cases, be used as a basis for modeling and understanding human diseases. Biomedical scientists face a challenge to choose the correct animal model to study disease pathology, and neurological diseases are no exception to this rule. <p> Animal Models for Neurological Disorders covers different animal models which have been used for studying neurological disorders. 13 topical chapters have been contributed by a group of experts on the subject with an aim to cover emerging experimental models of a range of neurological diseases encountered in the clinic including Alzheimer’s disease, psychosis, Parkinson’s, Huntington’s disease, vascular dementia, schizophrenia, multiple sclerosis and brain tumors, among others. The chapters also inform readers about relevant clinical correlations in each disease model where appropriate. <p> Animal Models for Neurological Disorders is intended for all scholarly researchers and students of biomedical sciences, pharmacology, medicine (oncology, neurology, psychiatry), pharmacy, biochemistry, and biotechnology. The organized contents of the book also serve as a quick reference point for scientists working in applied areas of neuroscience including the study of neurodegenerative diseases and cognitive dysfunction in living organisms.

Among neurodegenerative diseases, those that lead to a state of dementia are the aim of several investigations. Dementia is a chronic disease the prevalence of which is increasing worldwide. The number of dementia patients in the world is approximately 50 million, and it is estimated that the number of patients will reach 131.5 million by 2050. This increase will be accompanied by a significant increase in medical expenditures and other expenses, especially for elderly patients. Therefore, the maintenance cost of dementia in the future is expected to be quite high. For this reason, several investigations aim, firstly, to describe the key mechanisms involved in the origin of dementia and, secondly, to establish preventive and therapeutic strategies in order to understand and mitigate this debilitating pathology. &lt;p&gt; This volume of Frontiers in Clinical Drug Research - Dementia explores the current comorbidities that cause cognitive impairment and the current management alternatives for clinical cases of dementia. The reviews contributed in these volume will provide readers with a current perspective on the subject. The topics covered in this volume include: &lt;p&gt; - Comorbidities inducing mild cognitive impairment - an evaluation of the risk caused by some pathological conditions &lt;p&gt; - Tau-targeted therapy in Alzheimer's disease - history and current state &lt;p&gt; - Emerging nanotherapeutic strategies in Alzheimer's disease &lt;p&gt; - Implication of dehydroepiandrosterone on dementia related to oxidative stress &lt;p&gt; - Polyphenol compounds as potential therapeutic agents in Alzheimer&rsquo;s disease &lt;p&gt; The volume is a timely update on dementia treatment for clinical physicians, neurologists, gerontologists, pharmaceutical and medicinal chemistry researchers, and physiologists.

Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of central nervous system (CNS) and other nerve disorders. The scope of the book series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of contemporary molecular targets involved in neurological and CNS disorders. Reviews presented in the series are mainly focused on clinical and therapeutic aspects of novel drugs intended for these targets. Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critical information for developing clinical trials and devising research plans in the field of neurology. The ninth volume of this series features reviews that cover the following topics related to the treatment of a different CNS disorders, related diseases and basic neuropharmacology research: - Integrating imaging and microdialysis into systems neuropharmacology - Depression heterogeneity and the potential of a transdiagnostic and dimensional approach to identify biologically relevant phenotypes - CAR-T cells in brain tumors and autoimmune diseases &ndash; from basics to the clinic - Revaluation of thyrotropin-releasing hormone and its mimetics as candidates for treating a wide range of neurological and psychiatric disorders - Natural BACE1 inhibitors: promising drugs for the management of Alzheimer&rsquo;s disease - The possibilities of safe lithium therapy in the treatment of neurological and psychoemotional disorders - Pharmacotherapy of multiple sclerosis and treatment strategies

Frontiers in Anti-Cancer Drug Discovery is a book series devoted to publishing the latest advances in anti-cancer drug design and discovery. In each volume, eminent scientists contribute reviews relevant to all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The book series should prove to be of interest to all pharmaceutical scientists involved in research in anti-cancer drug design and discovery. The book series is essential reading to all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field. This volume of the series focuses on reviews of treatments derived from natural sources (cannabinoid-based medicines and turmeric), immunotherapy, biomarkers for glioblastoma and some new drug targets for anti-cancer treatment. The reviews included in this volume are: - Cannabinoid-Based Anticancer Strategies: - The Beneficial Effects of Turmeric and Its Active Constituent in Cancer Treatment - Immunotherapy Approaches Focusing on Cancer Stem Cells - Immunotherapy for the Treatment of Hepatocellular Carcinoma - Role of Biomarkers in Developing Therapies for Glioblastoma Multiforme - Poly (ADP-ribose) Polymerases as New Drug Targets in Cancer Treatment

Postbiotics: Science, Technology, and Applications explains fundamental and applied knowledge about postbiotics. Chapters cover the definition and classification of postbiotics, principal methods for preparing them, information about the main postbiotic constituents and their biological activities and their clinical health benefits. The authors also familiarize the reader with potential applications of postbiotics in the food industry, pharmaceutical chemistry, medicine, and veterinary practice. The text is supported by informative illustrations, tables, and references for further reading. This comprehensive reference, with its emphasis on both basic and applied knowledge, is useful for researchers, academics, veterinarians, and students in the field of microbiology, immunology, pharmacology, biotechnology, food science, and agriculture.

Researchers have tried various effective treatments that prevent the progressive neurodegeneration of neurons within the brain. Parkinson’s disease (PD), Alzheimer’s disease (AD), and Multiple sclerosis (MS) are some of the most common neurodegenerative diseases (NDDs). Recent Advances in the Treatment of Neurodegenerative Disorders provides interesting updates on treatments of these neurological disorders. Ten chapters have been contributed by experts in pharmacology and give a unique perspective to reader on special topics in this area, including the treatment of neurodegenerative treatment of neurodegenerative disease through ayurveda and phytochemicals, the therapeutic role of vitamins in Parkinson’s disease, mushrooms in NDD treatment, MS treatment, ALS treatment and the use of nanoparticles and nano formulations in NDD treatment. This is an informative reference for pharmacologists, medicinal chemists and healthcare professionals (general practitioners and neurologists) seeking updates in the treatment of some common neurodegenerative disorders.

Frontiers in Drug Design and Discovery is a book series devoted to publishing the latest and the most important advances in drug design and discovery. Eminent scientists have contributed chapters focused on all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, and structure-activity relationships. This book series should prove to be of interest to all pharmaceutical scientists who are involved in research in drug design and discovery and who wish to keep abreast of rapid and important developments in the field. The tenth volume of this series brings together reviews covering topics related to the treatment of neoplasms, systems biology, respiratory diseases among others. Topics included in this volume are: - Recombinant Protein Production: from Bench to Biopharming - Plant Virus Nanoparticles and Virus like Particles (VLPs): Applications in Medicine - MAO Inhibitory Activity Of 4, 5-Dihydro-1 HPyrazole Derivatives: A Platform To Design Novel Antidepressants - Flavonoids Antagonize Effects of Alcohol in Cultured Hippocampal Neurons: A Drug Discovery Study - Hybrid Smart Materials for Topical Drug Delivery: Application of Scaffolds

Both Asia and Africa are home to many plants that can be used for the treatment of many diseases and their medicinal properties are gaining interest in western societies. Medicinal plants from Asia and Africa are used for their healing abilities and also have a symbolic meaning in communities. The importance of traditional autochthonous plant remedies plays a crucial role in the health of millions of people of these two continents. Even today, traditional medicine represents the dominant medical system for millions of people showing a significant impact on health care practices. Therefore, traditional operators still represent a vital part of regional healthcare systems. For this reason, pharmaceutical industries consider traditional medicine as a source for the identification of bioactive compounds that can be used in the preparation of synthetic drugs. Biologically Active Natural Products from Asia and Africa: A Selection of Topics guides the reader to information about new natural products from these regions and the different ways to use them to treat or alleviate many of the most common diseases. The volume presents nine topics covering a number of facets of natural product medicine including: - pharmaceutical analysis of anti-diabetic herbal medicines from Bangladesh and local retailers - caffeine intake and the risk of female infertility - pharmaceutical analysis of Urena sinuata (bur mallow) - anti-CHIKV activities of diterpenes and their derivatives - anti-inflammatory nanogel for the treatment of psoriasis - antlithiatic properties of Moroccan medicinal plants - ethnobotanic, phytochemical and biological activities of Aristolochia longa L. (pipevine) - wound healing potential of combined extracts of stem bark and leaves of sphenocentrum jollyanum (an African shrub) This is a handy reference for specialists and R&D experts in pharmaceutical chemistry who wish to be informed about current knowledge on developing natural remedies in Asia and Africa

Obesity is a complex health problem, caused by a number of factors such as excessive food intake, lack of physical activity, genetic predisposition, endocrine disorders, medications and psychiatric illnesses. The incidence of obesity among populations in both the developing and the developed world has reached epidemic proportions. In response to this, efforts to control and treat obesity have also been vigorously pursued, ranging from activities focused on raising awareness about lifestyle changes to the discovery and development of safe and effective anti-obesity drugs. Anti-obesity Drug Discovery and Development is a book series focused on this very important area of healthcare research. Each volume presents insightful updates on pharmaceutical research and development for clinical researchers and healthcare professionals involved in obesity treatment programs. The fifth volume of this series is a compilation of 6 reviews of interesting topics on the subject that highlight different aspects of obesity treatment and management, some of which are novel approaches. Topics covered in this volume include: - the effect of sleep on weight and obesity management - AMPK as a postulated target for metabolic syndrome and obesity - Harnessing addiction neuroscience to treat obesity - Current treatment of obesity versus the next generation of anti-obesogenic drugs: an ecologically and sustainable approach to health - Leptin and leptin sensitizers for the treatment of obesity related conditions - MicroRNAs as targets for the management of obesity